ARNA - Arena Pharmaceuticals Stock Trading

What do drugs for weight loss, pulmonary hypertension, and irritable bowel syndrome all have in common? Not much -- except they are all offerings in which Arena Pharmaceuticals (NASDAQ: ARNA) has come close to the finish line over the past two decades, only to come up short. IMA...

- Olorinab investigated in three doses, 10 mg, 25 mg, and 50 mg, for abdominal pain associated with IBS-C & IBS-D - Trial did not meet primary endpoint in broad study population - Moderate to severe pain population at 50 mg showed statistically significant, clinica...

Image source: The Motley Fool. Arena Pharmaceuticals Inc (NASDAQ: ARNA) Q4 2020 Earnings Call Feb 23, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Arena Pharmaceuticals Inc (ARNA) Q4 2020 Earnings Call Transcript...